Global Microbial Contract Biomanufacturing Market (2020 to 2030) – Industry Trends and Global Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Microbial Contract Biomanufacturing Market across Type of Biologic, Type of Microbial Expression System Used, Scale of Operation, End User, and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.

The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. The study also features a detailed analysis of key drivers and trends related to this evolving domain.

Traditionally, microbial cell cultures have been the preferred choice for the production of the variety of biologics, including peptide therapeutics and certain low molecular weight proteins (insulin) and cytokines. Till date, over 60% of recombinant proteins used for therapeutic purposes, are estimated to be produced using microbial expression systems, primarily Escherichia coli. In fact, more than 70 biologics approved by various regulatory authorities, worldwide, are manufactured using microbial fermentation. It is worth highlighting that the growing interest in certain novel biologics, such as antibody fragments and plasmid DNA (with potential application areas in cell and gene therapies, and DNA vaccines), has led to a substantial increase in demand for microbial system-based production. Furthermore, evolutionary advances in manufacturing technologies have resulted in a renewed interest from drug developers in using microbial platforms for the production of complex biologics.

Given the inherent complexities in the development and production of biologics, drug developers have demonstrated the preference to outsource parts of their microbial manufacturing operations, as well. In fact, there has been a rise in the outsourcing activity in relation to microbial fermentation since 2017. Presently, the microbial contract biomanufacturing market features a mix of small, mid-sized and large players, offering end-to-end solutions, ranging from early stage process development to clinical and commercial scale manufacturing and regulatory filing. Despite this being a fairly well-established domain, more than 25 new contract microbial fermentation companies have been established over the last decade.

Therefore, in order to remain competitive, CMOs/CDMOs have begun active in acquiring cutting-edge fermentation technologies and investing in the development of the necessary capacity to support the growing demand for novel biologics. It is also worth highlighting that the COVID-19 pandemic is also likely to create significant business opportunities for microbial CMOs as innovator companies are expected to seek support in manufacturing of potential vaccines and other therapeutic modalities. In the long term, we are led to believe that the contract services market catering to this segment of the biopharma industry is anticipated to witness substantial growth in the coming years. (Read more…)

Key Questions Answered

• Who are the leading CMOs with expertise in production of microbial biologics?
• What are the preferred microbial expression systems used in biologic development and manufacturing?
• What are the key microbial fermentation technology platforms?
• Who could be the potential partners for the microbial CMOs?
• What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
• What type of expansion initiatives are being carried out by CMOs in this domain?
• What initiatives are being undertaken by big pharma players in this domain?
• What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to microbial fermentation?
• What are the key trends within the microbial contract biomanufacturing market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE

5. COMPANY COMPETITIVENESS ANALYSIS

6. COMPANY PROFILES

7. RECENT PARTNERSHIPS

8. RECENT EXPANSIONS

9. MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS

10. ASSESSMENT OF RELATIVE COMPETITION AND GROWTH

11. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

12. BIG PHARMA INITIATIVES IN MICROBIAL BIOMANUFACTURING

13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE

13.1. Chapter Overview

13.2. Small Molecule and Large Molecule Drugs / Therapies

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

15. IMPACT OF COVID-19 PANDEMIC ON MICROBIAL CONTRACT BIOMANUFACTURING MARKET

15.1. Chapter Overview

15.2. Current Options and Recuperative Initiatives of Key Players

15.2.1. KBI Biopharma

15.2.2. Lonza

15.2.3. Porton Pharma Solutions

15.2.4. Wacker Biotech

15.2.5. Wuxi AppTec

15.3. Impact on Microbial Contract Biomanufacturing Market Opportunity

16. SWOT ANALYSIS

17. CONCLUSION

18. INTERVIEW TRANSCRIPTS

19. APPENDIX 1: TABULATED DATA

Companies Mentioned

• 3P Biopharmaceuticals
• 3SBio
• 53Biologics
• AbbVie
• AbbVie Contract Manufacturing
• Adare Pharmaceuticals
• ADL Bionatur Solutions
• ADL BioPharma
• ADM Biopolis
• Advaxis
• Affibody
• Affinity Life Sciences
• AGC Biologics
• Ajinomoto Bio-Pharma Services
• Akers Biosciences
• Akshaya Bio
• Aldevron
• Allergan
• Alliance Protein Laboratories
• Altor BioScience
• Amgen
• AMRI
• Arranta Bio
• AstraZeneca
• Aumgene Biosciences
• AURA Biotechnologies
• Axcellerate Pharma
• BacThera
• Batavia Biosciences
• Bexion Pharmaceuticals
• BIA Separations
• BINEX
• Bio Elpida
• BioCell
• Biological E.
• BioMARC
• Biomay
• Biomeva (Acquired by AGC)
• Bionaturis
• BioProduction by Sekisui
• Biose industrie
• Biosynergy (Europe)
• Bio-Synthesis
• Bio-Technology General
• BioVectra
• Biovian
• BJP Laboratories
• Boehringer Ingelheim
• Boehringer Ingelheim BioXcellence
• Boston Institute of Biotechnology
• Bristol-Myers Squibb
• And Many More Companies!

For more information about this report visit https://www.researchandmarkets.com/r/ti1yib

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900